The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
about
Preclinical validation of interleukin 6 as a therapeutic target in multiple myelomaRecent advances in antimultiple myeloma drug development.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenGP130 activation induces myeloma and collaborates with MYC.Complexity of molecular alterations impacts pancreatic cancer prognosis.Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancyPhosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.JAK2 inhibition for the treatment of hematologic and solid malignancies.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Selective JAK inhibitors.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonCladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia.From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways.
P2860
Q27027729-F10C0A97-7A17-4034-ACAD-A8214B8E24CAQ33416297-D7969247-5A73-4E86-BED0-3CBB10545E42Q33628532-AE5B6A04-80E9-4BE7-BB61-1EF53AC83E5AQ35145350-78989ED0-4F1D-4091-9FED-BA834D9F6198Q36563027-33582AFE-7131-4EBE-B9B1-FE71EF2823A9Q36737884-7951143E-08A5-42D5-B38A-06EC5F659401Q37073598-006C8B26-FEF4-4D7A-ABF3-773C9A75D0CBQ37697253-F47B3CEA-630D-410E-AE28-9C50FF80FDD3Q37705457-023AE3DA-3065-409E-8BD4-1D14274463CFQ38001733-AEB8F8F5-2732-455F-8CA1-28435D6A384CQ38044736-8A7B14A2-46ED-4A5C-9F13-59D411B65408Q38077992-5322CBF6-B20C-47A4-A1E2-08BC3ECC1835Q38164139-ACDA1690-B40B-4FE3-94D3-E67ED552D8BBQ38203779-9DB6EB4D-97AA-4472-BB5F-AFC5CA5E70CBQ38261371-E8AADDD2-5CC3-4C1B-8BE8-ACAA03F6FEE6Q38478630-893785DE-BBB0-49C0-B16A-B6B0E2B94194Q43103345-5EAF427F-F9AF-4971-931A-F5A36A94A2B4Q47099145-56B9A3CE-4470-4483-9341-D93BF7B9DCE1Q49872904-413BF147-A155-4AB7-AAE5-0AB96EF4154AQ53120406-6CA45D62-737E-4BFA-B7FB-6E5ED88A1290Q53303327-EAC0E4A9-0188-431D-8535-BE668444B021Q54114902-2447B5C6-53AC-40DF-A307-16519E9724A7Q55292078-C02F0E90-9E83-41C5-BD63-A64A0BEEBCBB
P2860
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@en
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@nl
type
label
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@en
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@nl
prefLabel
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@en
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@nl
P2093
P2860
P356
P1433
P1476
The novel JAK inhibitor CYT387 ...... pically diverse myeloma cells.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2011.175
P577
2011-07-26T00:00:00Z